Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2010. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a regulatory disclosure of share ownership changes and does not contain financial performance data.
Material Changes
The material change reported is the acquisition of Ordinary shares by specific company personnel on July 9, 2010. These transactions occurred at a price of £11.33 per share through the Dividend Reinvestment element of the Company's Share Reward Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Date: July 9, 2010.
- Share Price: £11.33 per Ordinary share.
- Participants: Acquisitions were made by Mr A P Witty, Mr J S Heslop, Mr S M Bicknell, Mr E J Gray, Mr S A Hussain, Mr D Learmouth, Dr D Pulman, Mr D S Redfern, Ms C Thomas, and Mr P J T Vallance.
- Volume: Most participants acquired 31 shares; Mr S A Hussain acquired 6 shares; Dr D Pulman acquired 12 shares; Mr P J T Vallance acquired 11 shares.
- Notification Date: The company and relevant persons were advised of this information on July 12, 2010.